开发用于癌症治疗的蛋白酶体抑制剂

Xu Chen, Xuan Wu, Linyan Li, Xiaoming Zhu
{"title":"开发用于癌症治疗的蛋白酶体抑制剂","authors":"Xu Chen, Xuan Wu, Linyan Li, Xiaoming Zhu","doi":"10.53941/ijddp.2024.100004","DOIUrl":null,"url":null,"abstract":"Review\nDevelopment of Proteasome Inhibitors for Cancer Therapy\n\nXu Chen † , Xuan Wu † , Linyan Li, and Xiaoming Zhu *\n\n\nState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China\n* Correspondence: xmzhu@must.edu.mo\n \n \nReceived: 12 January 2024\nAccepted: 19 February 2024\nPublished: 18 March 2024\n \n\nAbstract: The ubiquitin proteasome system (UPS) is considered a crucial degradation machinery in cellular processes of protein quality control and homeostasis. Dysregulation of the UPS is closely associated with many diseases. The proteasome is a key core component of the UPS, which can prevent the accumulation of misfolded proteins and regulate various cellular processes such as cell cycle, apoptosis, and immune responses. In the past two decades, a total of three proteasome inhibitors have been approved for the treatment of hematological malignancies, including bortezomib, carfilzomib, and ixazomib. Additionally, accumulating reports have suggested that some natural product-derived proteasome inhibitors have been developed as anti-cancer drug candidates. In this review, we summarize the development of proteasome inhibitors as well as the mechanisms involved, clinical application progress, and drug resistance. The natural products of proteasome inhibitors and their future perspectives will also be discussed.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of Proteasome Inhibitors for Cancer Therapy\",\"authors\":\"Xu Chen, Xuan Wu, Linyan Li, Xiaoming Zhu\",\"doi\":\"10.53941/ijddp.2024.100004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Review\\nDevelopment of Proteasome Inhibitors for Cancer Therapy\\n\\nXu Chen † , Xuan Wu † , Linyan Li, and Xiaoming Zhu *\\n\\n\\nState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China\\n* Correspondence: xmzhu@must.edu.mo\\n \\n \\nReceived: 12 January 2024\\nAccepted: 19 February 2024\\nPublished: 18 March 2024\\n \\n\\nAbstract: The ubiquitin proteasome system (UPS) is considered a crucial degradation machinery in cellular processes of protein quality control and homeostasis. Dysregulation of the UPS is closely associated with many diseases. The proteasome is a key core component of the UPS, which can prevent the accumulation of misfolded proteins and regulate various cellular processes such as cell cycle, apoptosis, and immune responses. In the past two decades, a total of three proteasome inhibitors have been approved for the treatment of hematological malignancies, including bortezomib, carfilzomib, and ixazomib. Additionally, accumulating reports have suggested that some natural product-derived proteasome inhibitors have been developed as anti-cancer drug candidates. In this review, we summarize the development of proteasome inhibitors as well as the mechanisms involved, clinical application progress, and drug resistance. The natural products of proteasome inhibitors and their future perspectives will also be discussed.\",\"PeriodicalId\":94047,\"journal\":{\"name\":\"International journal of drug discovery and pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of drug discovery and pharmacology\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.53941/ijddp.2024.100004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of drug discovery and pharmacology","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.53941/ijddp.2024.100004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

综述蛋白酶体抑制剂在癌症治疗中的开发陈旭 † ,吴璇 † ,李林燕,朱晓明 *澳门科技大学澳门医药卫生应用研究院中医药质量研究国家重点实验室,中国澳门特别行政区氹仔,999078* 通讯地址:xmzhu@must.edu.mo 收稿日期:2024 年 1 月 12 日收稿日期:2024 年 1 月 12 日12 January 2024Accepted:19 February 2024Published: 18 March 2024 摘要:泛素蛋白酶体系统(UPS)被认为是细胞蛋白质质量控制和平衡过程中的关键降解机制。UPS 的失调与许多疾病密切相关。蛋白酶体是 UPS 的关键核心成分,它可以防止错误折叠蛋白的积累,并调节细胞周期、细胞凋亡和免疫反应等各种细胞过程。在过去二十年中,共有三种蛋白酶体抑制剂被批准用于治疗血液恶性肿瘤,包括硼替佐米、卡非佐米和伊沙佐米。此外,越来越多的报道表明,一些天然产物衍生的蛋白酶体抑制剂已被开发为抗癌候选药物。在这篇综述中,我们总结了蛋白酶体抑制剂的发展、相关机制、临床应用进展和耐药性。此外,还将讨论蛋白酶体抑制剂的天然产物及其未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development of Proteasome Inhibitors for Cancer Therapy
Review Development of Proteasome Inhibitors for Cancer Therapy Xu Chen † , Xuan Wu † , Linyan Li, and Xiaoming Zhu * State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China * Correspondence: xmzhu@must.edu.mo     Received: 12 January 2024 Accepted: 19 February 2024 Published: 18 March 2024   Abstract: The ubiquitin proteasome system (UPS) is considered a crucial degradation machinery in cellular processes of protein quality control and homeostasis. Dysregulation of the UPS is closely associated with many diseases. The proteasome is a key core component of the UPS, which can prevent the accumulation of misfolded proteins and regulate various cellular processes such as cell cycle, apoptosis, and immune responses. In the past two decades, a total of three proteasome inhibitors have been approved for the treatment of hematological malignancies, including bortezomib, carfilzomib, and ixazomib. Additionally, accumulating reports have suggested that some natural product-derived proteasome inhibitors have been developed as anti-cancer drug candidates. In this review, we summarize the development of proteasome inhibitors as well as the mechanisms involved, clinical application progress, and drug resistance. The natural products of proteasome inhibitors and their future perspectives will also be discussed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信